

桃園長庚紀念醫院

抗生素敏感性試驗

2022年報

JAN. ~DEC.

檢驗醫學部 微生物組

感染管制委員會

製表

GRAM (-) BACILLI

JAN. ~ DEC., 2022

ANTIBIOTICS BACTERIA	TOTAL (no.)*	PERCENT OF SUSCEPTIBILITY**																		
		AMC	AN	CAZ	CIP	CL	CPS	CRO	CXM	CZ	DOR	ETP	FEP	GM	IPM	LVX	MEM	SAM	SXT	TZP
Citrobacter koseri	43	86	100	86	95	-	91	84	81	79	-	95	-	98	-	98	-	86	97	93
Escherichia coli	879	77	100	73	52	-	98	72	69	41	-	99	-	81	-	59	-	65	60	98
Klebsiella pneumoniae	186	65	97	76	56	-	89	77	63	55	-	91	-	77	-	69	-	71	54	82
Proteus mirabilis	92	76	99	88	54	-	100	90	88	21	-	100	-	70	-	65	-	75	42	100
Pseudomonas aeruginosa	124	-	100	99	83	100	96	-	-	-	96	-	98	97	90	81	93	-	-	96

AMC=amoxicillin/clavulanic acid; AM=ampicillin; AN=amikacin; CAZ=ceftazidime; CIP=ciprofloxacin; CL=colistin; CLR=clarithromycin; CPS=cefoperazone-sulbactam; CRO=ceftriaxone; CXM=cefuroxime; CZ=cefazolin; DOR=doripemun; ETP=ertapenem; FEP=cefepime; GM=gentamicin; IPM=imipenem; LVX=levofloxacin; MEM=meropenem; SAM=ampicillin-sulbactam; SXT=sulfamethoxazole-trimethoprim; TZP=piperacillin-tazobactam; - =not tested or not available

*紅字代表細菌數目較去年多10%以上; 藍字代表較去年少10%以上

**紅字代表藥敏性較去年數字低10以上; 藍字代表較去年高10以上

**本表格資料乃統計所有病人在此統計時段內於本院經細菌培養所得第一次藥敏試驗結果, 僅供醫師經驗性選擇抗生素時參考之用; CR或MDR菌株均已併入原菌株結果一起檢視.

GRAM (+) BACTERIA

JAN. ~ DEC., 2022

ANTIBIOTICS BACTERIA	TOTAL (no.)*	PERCENT OF SUSCEPTIBILITY**														
		AM	CC	CRO	E	FA	HGM	LVX	LZD	MXF	OX	P	SXT	TEC	TGC	VA
Beta strep group B	100	100	56	100	47	-	-	-	-	-	-	100	-	100	-	100
Enterococcus faecalis	153	100	-	-	-	-	63	-	-	-	-	97	-	100	-	100
Enterococcus faecium	40	0	-	-	-	-	68	-	100	-	-	0	-	25	100	25
Staphylococcus aureus	191	-	75	-	41	95	-	-	100	-	58	7	98	100	100	100
Staphylococcus epidermidis	122	-	57	-	41	-	-	-	-	-	41	12	80	100	-	100
Streptococcus pneumoniae	2	-	-	#	-	-	-	100	-	100	-	#	-	-	-	100

AM=ampicillin; CC=clindamycin; CRO=ceftriaxone; E=erythromycin; FA=fusidic acid; HGM= high level gentamicin; LVX=levofloxacin; LZD=linezolid;
MXF=moxifloxacin; OX=oxacillin; P=penicillin-G; SXT = sulfamethoxazole-trimethoprim; TEC=teicoplanin; TGC=tigecyclin; VA=vancomycin;

- = not tested or not available

Streptococcus pneumoniae對penicillin與ceftriaxone的藥敏結果綜合整理於最後

*紅字代表細菌數目較去年多10%以上; 藍字代表較去年少10%以上;

**紅字代表藥敏性較去年數字低10以上; 藍字代表較去年高10以上

**本表格資料乃統計所有病人在此統計時段內於本院經細菌培養所得第一次藥敏試驗結果, 僅供醫師經驗性選擇抗生素時參考之用.

Anaerobes

JAN. ~ DEC., 2022

ANTIBIOTICS BACTERIA@	TOTAL (no.)*	PERCENT OF SUSCEPTIBILITY **				
		CC	MET	P	PIP	SAM
Fingoldia magna	35	63	100	100	100	100

CC=clindamycin; MET=metronidazole; P=penicillin-G; PIP=piperacillin; SAM = ampicillin-sulbactam

*紅字代表細菌數目較去年多10%以上; 藍字代表較去年少10%以上

**紅字代表藥敏性較去年數字低10以上; 藍字代表較去年高10以上

@本年度新上榜的細菌名稱以紅字標示;

*本表格資料乃統計所有病人在此統計時段內於本院經細菌培養所得
第一次藥敏試驗結果, 僅供醫師經驗性選擇抗生素時參考之用

Streptococcus pneumoniae

JAN. ~ DEC., 2022

抗生素 種類	檢體別	判讀標準	結果分類	全院		
			(濃度範圍, mg/L)	總菌株數*	菌株數	%**
Penicillin-G	CSF	meningitis 標準	S (≤ 0.06)	0	0	0.0
			-		-	-
			R (≥ 0.12)		0	0.0
	Other invasive specimens	meningitis 標準	S (≤ 0.06)	0	0	0.0
			-		-	-
			R (≥ 0.12)		0	0.0
		non- meningitis 標準	S (≤ 2)		0	0.0
			I (4)		0	0.0
			R (≥ 8)		0	0.0
	Non- invasive specimens	non- meningitis 標準	S (≤ 2)	2	2	100.0
			I (4)		0	0.0
			R (≥ 8)		0	0.0
Ceftriaxone	CSF	meningitis 標準	S (≤ 0.5)	0	0	0.0
			I (1)		0	0.0
			R (≥ 2)		0	0.0
	Other invasive specimens	meningitis 標準	S (≤ 0.5)	0	0	100.0
			I (1)		0	0.0
			R (≥ 2)		0	0.0
		non- meningitis 標準	S (≤ 1)		0	100.0
			I (2)		0	0.0
			R (≥ 4)		0	0.0
	Non- invasive specimens	non- meningitis 標準	S (≤ 1)	2	2	100.0
			I (2)		0	0.0
			R (≥ 4)		0	0.0

*紅字代表細菌數目較去年多10%以上；藍字代表較去年少10%以上

**紅字代表藥敏性較去年數字低10以上；藍字代表較去年高10以上

GRAM (-) BACILLI - nosocomial isolates only
NOSOCOMIAL ISOLATES ONLY
202001-202212

ANTIBIOTICS BACTERIA	TOTAL (no.)	PERCENT OF SUSCEPTIBILITY**																
		AMC	AN	CAZ	CIP	CPS	CRO	CXM	CZ	DOR	ETP	FEP	GM	IPM	LVX	MEM	SXT	TZP
Escherichia coli &	81	65	100	59	33	96	42	41	24	-	99	32	70	-	43	-	46	95
Klebsiella pneumoniae &&	38	49	92	83	37	87	65	52	37	-	89	24	62	-	49	-	42	73
Pseudomonas aeruginosa	25	-	100	92	80	84	-	-	-	96	-	96	92	84	76	96	-	88

AMC=amoxicillin/clavulanic acid; AN=amikacin; CAZ=ceftazidime; CIP=ciprofloxacin; CPS=cefoperazone-sulbactam; CRO=ceftriaxone; CXM=cefuroxime; CZ=cefazolin; DOR=doripemun; ETP=ertapenem; FEP=cefepime; GM=gentamicin; IPM=imipenem; LVX=levofloxacin; MEM=meropenem; SXT=sulfamethoxazole-trimethoprim; TZP=piperacillin-tazobactam; - =not tested or not available

&上表中所列數字, 已包含CR及菌株 1 株(1%)

&&上表中所列數字, 已包含CR及MDR菌株 4 株(11%)

**GRAM (+) BACTERIA
NOSOCOMIAL ISOLATES ONLY
202001-202212**

ANTIBIOTICS BACTERIA	TOTAL (no.)	PERCENT OF SUSCEPTIBILITY**											
		AM	CC	E	FA	HGM	LZD	OX	P	SXT	TEC	TGC	VA
Enterococcus faecalis	11	100	-	-	-	55	-	-	100	-	100	-	100
Staphylococcus aureus ^{&}	13	-	75	63	91	-	100	45	0	91	100	100	100

AM=ampicillin; CC=clindamycin; E=erythromycin; FA=fusidic acid; HGM= high level gentamicin; LZD=linezolid;

OX=oxacillin; P=penicillin-G; SXT = sulfamethoxazole-trimethoprim; TEC=teicoplanin; TGC=tigecyclin; VA=vancomycin;

- = not tested or not available

& S. aureus含MRSA 8株 (40%)